RecruitingNot ApplicableNCT06493968

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With Placenta Accrete Spectrum Disorders Undergoing Cesarean Hysterectomy


Sponsor

Cairo University

Enrollment

70 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called oxytocin and placebo for people with placenta accreta spectrum. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 20 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGoxytocin

Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision

OTHERplacebo

IV bolus of normal saline immediately with the uterine incision


Locations(1)

Cairo University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06493968


Related Trials